Obesity Overgewicht, obesitas
Conditions
Interventions
6 g of fine (droplet size 1 micron) or coarse (droplet size 15 micron) oil emulsion will be administered to the duodenum or the ileum.
Sponsors
Jeroen Maljaars
Division of Gastroenterology-Hepatology
University Hospital Maastricht.
PO Box 5800
2602 AZ Maastricht
The Netherlands
Email:PWJ.Maljaars@intmed.unimaas.nl
Tel: +31(0)433882983
Fax: +31(0)433875006
Eligibility
Inclusion criteria
Inclusion criteria: 1. Signed informed consent form 2. Sex: male or female 3. Age: 18-55 years 4. Body Mass Index (BMI): 18-32 kg/m2
Exclusion criteria
Exclusion criteria: 1. Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol 2. Gastrointestinal or hepatic disorders influencing gastrointestinal absorption or transit 3. The use of psychotropic drugs, including: benzodiazepines or alcohol in excess of 21 units/week for males and 14 units/week for females 4. Concomitant medication that can increase gastric pH (e.g. antacids, protonpump-inhibitors, prostaglandins, anticholinergic agents, H2-receptor antagonists), or alter gastric emptying (e.g. metoclopramide, cisapride, domperidone and erythromycin, anticholinergics, tricyclic antidepresants, narcotic analgetics, adrenergic agents, calcium channel blockers), or alter intestinal transit (e.g. loperamide, chemical/osmotic/bulk laxatives) ,or influence satiety/energy intake (e.g. sibutramine, glucocorticoids, anabolic steroids) 5. Intolerance of Slim Fast product or of ingredients of the ad libitum meal 6. Pregnancy, lactation, wish to become pregnant during study, or having a positive pregnancy test at inclusion 7. Reported unexplained weight loss/gain of more than 2 kg in the month before the study enrollment 8. Eating disorders detected using the “SCOFF” questionnaire (in Dutch translation), and high or very high-restrained eaters as measured by the Dutch Eating Behavior Questionnaire (25;26) – see Appendix 1 and 2. 9. Blood donations less than three months previous to study enrollment 10. One or more of the following dietary habits: medically prescribed diets, weight reduction diets, or vegetarian/macrobiotic/biologically dynamic food habits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess whether the fat droplet size in an emulsion affects satiety (as measured by visual analogue scales) and food intake (during ad libitum lunch) when infused into the duodenum and when infused into the ileum. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess whether the fat droplet size in an emulsion affects gastric emptying, intestinal transit time and secretion of peptides known to affect satiety (CCK, PYY) when infused into the duodenum and when infused into the ileum. | — |
Contacts
Public ContactP.W.J. Maljaars
University Hospital Maastricht (azM) Department of Internal Medicine Divison of Gastroenterology & Hepatology PO Box 5800
Outcome results
None listed